Intestinal MYC modulates obesity-related metabolic dysfunction

• DOI: 10.1038/s42255-021-00421-8
• Publication Date: 2021-07-01T16:06:50Z
• Authors: Yuhong Luo; Shoumei Yang; Xuan Wu; Shogo Takahashi; Lulu Sun; Jie Cai; Kristopher W. Krausz; Xiaozhen Guo; Henrique B. Dias; Oksana Gavrilova; Cen Xie; Changtao Jiang; Weiwei Liu; Frank J. Gonzalez
• Keywords: Steatohepatitis; Steatosis; Ceramide synthase

MYC is a transcription factor with broad biological functions, notably in the control of cell proliferation. Here, we show that intestinal MYC regulates systemic metabolism. We find that MYC expression is increased in ileum biopsies from individuals with obesity and positively correlates with body mass index. Intestine-specific reduction of MYC in mice improves high-fat-diet-induced obesity, insulin resistance, hepatic steatosis and steatohepatitis. Mechanistically, reduced expression of MYC in the intestine promotes glucagon-like peptide-1 (GLP-1) production and secretion. Moreover, we identify Cers4, encoding ceramide synthase 4, catalysing de novo ceramide synthesis, as a MYC target gene. Finally, we show that administration of the MYC inhibitor 10058-F4 has beneficial effects on high-fat-diet-induced metabolic disorders, and is accompanied by increased GLP-1 and reduced ceramide levels in serum. This study positions intestinal MYC as a putative drug target against metabolic diseases, including non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.